Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | RECQL | P46063 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | NTRK1 | P04629 | 5/20 | 0.39 |
| ▸ | PIM1 | P11309 | 5/20 | 0.39 |
| ▸ | ACVR1 | Q04771 | 3/20 | 0.39 |
| ▸ | GAA | P10253 | 2/20 | 0.38 |
| ▸ | CCR1 | P32246 | 1/20 | 0.38 |
| ▸ | CCR5 | P51681 | 1/20 | 0.38 |
| ▸ | CCR8 | P51685 | 1/20 | 0.38 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | NOS3 | P29474 | 2/20 | 0.37 |
| ▸ | NOS2 | P35228 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30751791 | 1.00 | ALDH1A1 (0.40) | ALDH1A1SMN1; SMN2NPC1LMNAPOLB | |
| SCHEMBL27158634 | 0.83 | SMN1; SMN2 (0.40) | ALDH1A1SMN1; SMN2NPC1LMNAPOLB | |
| SCHEMBL15691383 | 0.80 | ALDH1A1 (0.39) | ALDH1A1SMN1; SMN2NPC1LMNAPOLB | |
| SCHEMBL15680079 | 0.80 | ROCK2 (0.39) | ALDH1A1SMN1; SMN2LMNARECQLNTRK1 | |
| SCHEMBL1261198 | 0.78 | NOS2 (0.54) | ALDH1A1SMN1; SMN2NPC1LMNAPOLB | |
| SCHEMBL3828718 | 0.78 | ALDH1A1 (0.44) | ALDH1A1SMN1; SMN2NPC1LMNAPOLB | |
| SCHEMBL1698600 | 0.78 | NTRK1 (0.42) | ALDH1A1LMNAPOLBHPGDRAB9A | |
| SCHEMBL677194 | 0.78 | L3MBTL1 (0.45) | ALDH1A1SMN1; SMN2NPC1LMNAPOLB | |
| SCHEMBL1721807 | 0.78 | PSMD14 (0.40) | ALDH1A1SMN1; SMN2NPC1LMNAPOLB | |
| SCHEMBL15691414 | 0.78 | NTRK1 (0.37) | ALDH1A1SMN1; SMN2LMNAPOLBHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240392220-A1 | BRANDY REPLICAS | AVA FOOD LABS, INC. | 2024-11-28 | — | — | US | disclosed |
| WO-2023179542-A1 | 5,8-DIHYDRO-1,7-NAPHTHYRIDINE DERIVATIVES AS GLP-1 AGONISTS FOR THE TREATMENT OF DIABETES | GASHERBRUM BIO , INC. (US) | 2023-09-28 | — | — | WO | disclosed |
| WO-2023172858-A1 | A PROCESS FOR PREPARING 4-METHYL-2-PROPAN-2-YL-PYRIDINE-3-CARBONITRILE | AMGEN INC. (US) | 2023-09-14 | — | — | WO | disclosed |
| WO-2023086799-A1 | HETEROCYCLIC COMPOUNDS AS TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS 2 AGONISTS | VIGIL NEUROSCIENCE, INC. (US) | 2023-05-19 | — | — | WO | disclosed |
| US-20230144095-A1 | PYRIDINE DERIVATIVES AND THEIR USE AS SODIUM CHANNEL ACTIVATORS | X-CHEM GLOBAL HQ | 2023-05-11 | — | — | US | disclosed |
| EP-3535258-B1 | SUBSTITUTED BICYCLE HETEROCYCLIC DERIVATIVES USEFUL AS ROMK CHANNEL INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2021-11-24 | — | — | EP | disclosed |
| EP-3535258-A1 | SUBSTITUTED BICYCLE HETEROCYCLIC DERIVATIVES USEFUL AS ROMK CHANNEL INHIBITORS | Bristol-Myers Squibb Company (US) | 2019-09-11 | — | — | EP | disclosed |
| CN-109890388-A | MAChR M4Positive allosteric modulators | 范德比尔特大学 | 2019-06-14 | — | — | CN | disclosed |
| CN-109863139-A | Muscarinic acetylcholine receptor M4Positive allosteric modulators of | 范德比尔特大学 | 2019-06-07 | — | — | CN | disclosed |
| WO-2018093569-A1 | SUBSTITUTED BICYCLE HETEROCYCLIC DERIVATIVES USEFUL AS ROMK CHANNEL INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2018-05-24 | — | — | WO | disclosed |
| US-7524870-B2 | Biaryloxymethylarenecarboxylic acids as glycogen synthase activators | HOFFMANN-LA ROCHE INC. (US) | 2009-04-28 | — | — | US | disclosed |
| US-20080255198-A1 | BIARYLOXYMETHYLARENECARBOXYLIC ACIDS AS GLYCOGEN SYNTHASE ACTIVATOR | CHU CHANG AN | 2008-10-16 | — | — | US | disclosed |
| US-20080108662-A1 | BIARYLOXYMETHYLARENECARBOXYLIC ACIDS AS GLYCOGEN SYNTHASE ACTIVATOR | CHU CHANG A | 2008-05-08 | — | — | US | disclosed |
| US-7355049-B2 | Biaryloxymethylarenecarboxylic acids as glycogen synthase activator | HOFFMANN-LA ROCHE INC. (US) | 2008-04-08 | — | — | US | disclosed |
| US-20060122256-A1 | Biaryloxymethylarenecarboxylic acids as glycogen synthase activators | GILLESPIE PAUL | 2006-06-08 | — | — | US | disclosed |
| EP-1458392-A4 | ACRIDONE INHIBITORS OF IMPDH ENZYME | BRISTOL MYERS SQUIBB CO (US) | 2005-06-08 | — | — | EP | disclosed |
| EP-1458392-A2 | ACRIDONE INHIBITORS OF IMPDH ENZYME | Bristol-Myers Squibb Company (US) | 2004-09-22 | — | — | EP | disclosed |
| US-6603007-B1 | Intermediates in the fields of pharmaceuticals, agrichemicals, ligands, silver halide photosensitive materials, liquid crystals, surfactants, electrophotography and organic electroluminescence | SANKIO CHEMICAL CO., LTD. (JP) | 2003-08-05 | — | — | US | disclosed |
| WO-2003059269-A2 | ACRIDONE INHIBITORS OF IMPDH ENZYME | BRISTOL-MYERS SQUIBB COMPANY (US) | 2003-07-24 | — | — | WO | disclosed |
| EP-1231207-A1 | NOVEL BIPYRIDYL DERIVATIVES | Sankio Chemical Co., Ltd. (JP) | 2002-08-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060122256-A1 | Biaryloxymethylarenecarboxylic acids as glycogen synthase activators | GYS2, GYS1, GSK3A | ALDH1A1 633/4885SMN1; SMN2 2097/4885NPC1 2787/4885 |
| US-20080108662-A1 | BIARYLOXYMETHYLARENECARBOXYLIC ACIDS AS GLYCOGEN SYNTHASE ACTIVATOR | GYS2, PYGL, GYS1 | ALDH1A1 499/4885SMN1; SMN2 1961/4885NPC1 1670/4885 |
| US-20230144095-A1 | PYRIDINE DERIVATIVES AND THEIR USE AS SODIUM CHANNEL ACTIVATORS | SCN1A, SCN1B, CACNA1A | ALDH1A1 1317/4885SMN1; SMN2 551/4885NPC1 1440/4885 |
| US-20080255198-A1 | BIARYLOXYMETHYLARENECARBOXYLIC ACIDS AS GLYCOGEN SYNTHASE ACTIVATOR | GYS2, PYGL, GYS1 | ALDH1A1 499/4885SMN1; SMN2 1961/4885NPC1 1670/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.